Skip to content

Study · Randomized controlled trial · 2025

6 results

Early-Onset Obesity and Tirzepatide Treatment: A Post Hoc Analysis of the SURMOUNT Clinical Trials.

Gourgari E, Srivastava G, Kelly AS, Mojdami D, Cao D, Murphy MA, Karanikas CA, Lee CJ

Obesity (Silver Spring, Md.)27 Jul 2025Cited by 4 (Europe PMC)

PMID40717199 (opens in a new tab)PMCIDPMC12381612 (opens in a new tab)DOI10.1002/oby.24348 (opens in a new tab)PepBankPUB-40717199
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, tirzepatide reduced body weight by similar amounts in people with early-onset and later-onset obesity (-23% vs -22%).

    In plain wordsIn adults with obesity, tirzepatide cut body weight by a similar amount whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody weight change at 72 weeks, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Body weight change
    −23%
    early-onset obesity
    Body weight change
    −22%
    later-onset obesity

    Source sentences

    Summary
    At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, tirzepatide reduced waist circumference by similar amounts in people with early-onset and later-onset obesity (-22 vs -19 cm).

    In plain wordsIn adults with obesity, tirzepatide cut waist size by a similar amount whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWaist circumference change at 72 weeks, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Waist circumference change
    −22 cm
    early-onset obesity
    Waist circumference change
    −19 cm
    later-onset obesity

    Source sentences

    Summary
    At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, tirzepatide reduced HbA1c by similar amounts in people with early-onset and later-onset obesity (-0.51% vs -0.52%).

    In plain wordsIn adults with obesity, tirzepatide lowered long-term blood sugar by a similar amount whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c change at 72 weeks, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    HbA1c change
    −0.51%
    early-onset obesity
    HbA1c change
    −0.52%
    later-onset obesity

    Source sentences

    Summary
    At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, tirzepatide reduced triglycerides by similar amounts in people with early-onset and later-onset obesity (-32% vs -31%).

    In plain wordsIn adults with obesity, tirzepatide lowered blood triglycerides by a similar amount whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTriglyceride change at 72 weeks, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Triglyceride change
    −32%
    early-onset obesity
    Triglyceride change
    −31%
    later-onset obesity

    Source sentences

    Summary
    At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-1, tirzepatide reduced systolic blood pressure by similar amounts in people with early-onset and later-onset obesity (-8 vs -8 mmHg).

    In plain wordsIn adults with obesity, tirzepatide lowered systolic blood pressure by a similar amount whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    DecreaseSystolic blood pressure change at 72 weeks, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Measurements

    Systolic blood pressure change
    −8 mmHg
    early-onset obesity
    Systolic blood pressure change
    −8 mmHg
    later-onset obesity

    Source sentences

    Summary
    At 72 weeks, improvements with tirzepatide in BW (-23% vs. -22%), WC (-22 vs. -19 cm), HbA1c (-0.51% vs. -0.52%), triglycerides (-32% vs. -31%), and SBP (-8 vs. -8 mmHg) were similar between subgroups.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In SURMOUNT-3 and SURMOUNT-4, improvements with tirzepatide were similar in people with early-onset and later-onset obesity.

    In plain wordsIn two more trials in adults with obesity, tirzepatide gave similar improvements whether obesity began before age 25 or later.

    Peptide
    Tirzepatide
    Outcome
    Not applicableImprovements in SURMOUNT-3 and SURMOUNT-4, early- versus later-onset obesity
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Similar improvements were observed in SURMOUNT-3 and SURMOUNT-4.
    1 context sentence
    Summary · context
    Participants (N = 3782) from SURMOUNT-1, SURMOUNT-3, and SURMOUNT-4 randomized to tirzepatide or placebo were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials3

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

3 trials · 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT04657016

A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

Eli Lilly and Companyn = 57929 Mar 2021 to 12 May 2023

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 16 May 2024
CompletedPhase 3Results postedNCT04660643

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

Eli Lilly and Companyn = 78329 Mar 2021 to 18 May 2023

Obesity · Overweight

Trial pageClinicalTrials.govUpdated 22 May 2024
CompletedPhase 3Results postedNCT04184622

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Eli Lilly and Companyn = 2,5394 Dec 2019 to 6 Jul 2024

Overweight · Obesity

Trial pageClinicalTrials.govUpdated 24 Jul 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.